Fig. 5: Trough FEV1 for percent predicted FEV1 at screening subgroups (ITT population). | npj Primary Care Respiratory Medicine

Fig. 5: Trough FEV1 for percent predicted FEV1 at screening subgroups (ITT population).

From: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

Fig. 5: Trough FEV1 for percent predicted FEV1 at screening subgroups (ITT population).The alternative text for this image may have been generated using AI.

Least squares mean (95% CI) change from baseline in trough FEV1 at a Day 28, b Day 84, and c Day 85. CFB change from baseline, CI confidence interval, FEV1 forced expiratory volume in 1 s, FF fluticasone furoate, ITT intent-to-treat, LS least squares, TIO tiotropium, UMEC umeclidinium, VI vilanterol.

Back to article page